首页 > 最新文献

Cardiovascular and Hematological Disorders - Drug Targets最新文献

英文 中文
Feasibility and Outcomes of Left Main to Branch Vessel PCI with Novel Tapered Coronary Stent in a Tertiary Care Centre: A Real World Experience. 在三级医疗中心使用新型锥形冠状动脉支架进行左主干至支支PCI的可行性和结果:一个真实的世界经验。
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871529X21666210812110944
T R Raghu, V A Sathwik Raj, J Kharge, H S Natraj Setty, Rahul S Patil, C N Manjunath

Objective: To assess the safety and efficacy of Novel tapered (BioMime™ Morph) sirolimus- eluting stent (SES) for left main PCI in a real-world scenario.

Background: Currently, no data is available on clinical usefulness of tapered ultrathin stents in left main PCI.

Methods: This was a prospective, non-randomised, single centre study carried out between February 2018 and May 2020 at a tertiary cardiac care centre in southern India. The study included patients treated with BioMime Morph tapered stent for distal de novo LMB lesion or ostial LAD/LCX lesions with significant size disparity between reference segments based on the eligibility criteria. Primary endpoint of the study was the cumulative incidence of major adverse cardiovascular events (MACE) composed of cardiac death, myocardial infarction, and clinically driven target-lesion revascularisation at follow-up.

Results: A total of 41 patients (average age of 54.83±9.81 years) were included in the study. Average SS-2 score was 23.17±5.42. Majority of the lesions (n=31; 75.61%) were of medina class (0.1.0). Provisional single stent strategy was adopted for treatment of LMB lesions. TIMI flow-3 was achieved in 40 patients (97.56%). Median clinical follow-up was 20 months (range 6-34 months). There was no periprocedural complication or MACE during follow-up.

Conclusion: Tapered stents may be an acceptable alternative for LM intervention in an anatomical subset of patients with tapered vessels.

目的:评估新型锥形(BioMime™Morph)西罗莫司洗脱支架(SES)用于左主干PCI的安全性和有效性。背景:目前,没有关于锥形超薄支架在左主干PCI中的临床应用的数据。方法:这是一项前瞻性、非随机、单中心研究,于2018年2月至2020年5月在印度南部的一家三级心脏护理中心进行。该研究纳入了采用BioMime Morph锥形支架治疗远端新生LMB病变或口侧LAD/LCX病变的患者,根据入选标准,参考节段之间存在显著的尺寸差异。该研究的主要终点是主要不良心血管事件(MACE)的累积发生率,包括心源性死亡、心肌梗死和临床驱动的靶病变血运重建。结果:共纳入41例患者,平均年龄54.83±9.81岁。平均SS-2评分为23.17±5.42分。大多数病变(n=31;75.61%)为麦地那类(0.1.0)。采用临时单支架策略治疗LMB病变。40例患者(97.56%)达到TIMI血流3。中位临床随访为20个月(范围6-34个月)。随访期间无围手术期并发症及MACE。结论:锥形支架可能是一种可接受的替代LM介入患者的锥形血管解剖亚群。
{"title":"Feasibility and Outcomes of Left Main to Branch Vessel PCI with Novel Tapered Coronary Stent in a Tertiary Care Centre: A Real World Experience.","authors":"T R Raghu,&nbsp;V A Sathwik Raj,&nbsp;J Kharge,&nbsp;H S Natraj Setty,&nbsp;Rahul S Patil,&nbsp;C N Manjunath","doi":"10.2174/1871529X21666210812110944","DOIUrl":"https://doi.org/10.2174/1871529X21666210812110944","url":null,"abstract":"<p><strong>Objective: </strong>To assess the safety and efficacy of Novel tapered (BioMime™ Morph) sirolimus- eluting stent (SES) for left main PCI in a real-world scenario.</p><p><strong>Background: </strong>Currently, no data is available on clinical usefulness of tapered ultrathin stents in left main PCI.</p><p><strong>Methods: </strong>This was a prospective, non-randomised, single centre study carried out between February 2018 and May 2020 at a tertiary cardiac care centre in southern India. The study included patients treated with BioMime Morph tapered stent for distal de novo LMB lesion or ostial LAD/LCX lesions with significant size disparity between reference segments based on the eligibility criteria. Primary endpoint of the study was the cumulative incidence of major adverse cardiovascular events (MACE) composed of cardiac death, myocardial infarction, and clinically driven target-lesion revascularisation at follow-up.</p><p><strong>Results: </strong>A total of 41 patients (average age of 54.83±9.81 years) were included in the study. Average SS-2 score was 23.17±5.42. Majority of the lesions (n=31; 75.61%) were of medina class (0.1.0). Provisional single stent strategy was adopted for treatment of LMB lesions. TIMI flow-3 was achieved in 40 patients (97.56%). Median clinical follow-up was 20 months (range 6-34 months). There was no periprocedural complication or MACE during follow-up.</p><p><strong>Conclusion: </strong>Tapered stents may be an acceptable alternative for LM intervention in an anatomical subset of patients with tapered vessels.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 2","pages":"128-135"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39307239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complications in Patients with Cardiac Penetrating Trauma. 心脏穿透伤患者的并发症。
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871529X21666211214155349
Mojtaba Ahmadinejad, Izadmehr Ahmadinejad, Leila Haji Maghsoudi, Ali Soltanian, Mehdi Safari

Background: Cardiac penetrating trauma is a medical emergency that mostly affects young people. Based on the type of injury and associated complications, it can present as a surgical challenge and can lead to mortality.

Objective: The aim of this study is to evaluate the complications of penetrating heart trauma among patients referred to Shahid Madani Hospital.

Methods: In this retrospective descriptive study, the data of penetrating cardiac trauma patients referred to Shahid Madani hospital, Karaj, Tehran, from 2016-2019, were investigated. Information, including age, sex, cause of trauma, traumatized area and complications, was extracted and recorded in a data collection form. The data were evaluated statistically using SPSS v18.

Results: A total of 44 patients were included in the study, where the mean age of the patients was 25 years. 73.3% of these patients were men and 26.7% were women. Knife stab wounds were the most prevalent cause of the trauma, present in 93.3% of patients. 73.3% of the patients had cardiac tamponade and 20% had a pneumothorax. The right ventricle was the most common site of the injury in 46.7% of the patients. A mortality rate of 3.4% was reported in this study.

Conclusion: The results of this study showed that the highest penetrating heart rate trauma occurred among young people, and the most common cause of the trauma was a knife stab. The most common area of the injury was the right ventricular, and cardiac tamponade was the most common complication.

背景:心脏穿透性创伤是一种主要影响年轻人的医疗急诊。根据损伤类型和相关并发症,它可能是一种手术挑战,并可能导致死亡。目的:本研究的目的是评估在Shahid Madani医院转诊的穿透性心脏创伤患者的并发症。方法:回顾性分析2016-2019年在德黑兰卡拉杰Shahid Madani医院就诊的穿透性心脏创伤患者的资料。提取包括年龄、性别、创伤原因、创伤区域和并发症在内的信息并记录在数据收集表中。采用SPSS v18对数据进行统计分析。结果:共纳入44例患者,患者平均年龄为25岁。其中男性占73.3%,女性占26.7%。刀伤是最常见的创伤原因,占93.3%的患者。73.3%的患者有心包填塞,20%的患者有气胸。右心室是最常见的损伤部位,占46.7%。本研究报告的死亡率为3.4%。结论:本研究结果表明,穿透性心率创伤发生在年轻人中,最常见的创伤原因是刀刺。最常见的损伤部位是右心室,心包填塞是最常见的并发症。
{"title":"Complications in Patients with Cardiac Penetrating Trauma.","authors":"Mojtaba Ahmadinejad,&nbsp;Izadmehr Ahmadinejad,&nbsp;Leila Haji Maghsoudi,&nbsp;Ali Soltanian,&nbsp;Mehdi Safari","doi":"10.2174/1871529X21666211214155349","DOIUrl":"https://doi.org/10.2174/1871529X21666211214155349","url":null,"abstract":"<p><strong>Background: </strong>Cardiac penetrating trauma is a medical emergency that mostly affects young people. Based on the type of injury and associated complications, it can present as a surgical challenge and can lead to mortality.</p><p><strong>Objective: </strong>The aim of this study is to evaluate the complications of penetrating heart trauma among patients referred to Shahid Madani Hospital.</p><p><strong>Methods: </strong>In this retrospective descriptive study, the data of penetrating cardiac trauma patients referred to Shahid Madani hospital, Karaj, Tehran, from 2016-2019, were investigated. Information, including age, sex, cause of trauma, traumatized area and complications, was extracted and recorded in a data collection form. The data were evaluated statistically using SPSS v18.</p><p><strong>Results: </strong>A total of 44 patients were included in the study, where the mean age of the patients was 25 years. 73.3% of these patients were men and 26.7% were women. Knife stab wounds were the most prevalent cause of the trauma, present in 93.3% of patients. 73.3% of the patients had cardiac tamponade and 20% had a pneumothorax. The right ventricle was the most common site of the injury in 46.7% of the patients. A mortality rate of 3.4% was reported in this study.</p><p><strong>Conclusion: </strong>The results of this study showed that the highest penetrating heart rate trauma occurred among young people, and the most common cause of the trauma was a knife stab. The most common area of the injury was the right ventricular, and cardiac tamponade was the most common complication.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 4","pages":"212-216"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39725742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Isosteviol Protects H9c2 Cells Against Hypoxia-reoxygenation by Activating ERK1/2. 异甜菊醇通过激活ERK1/2保护H9c2细胞抗缺氧再氧化。
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871529X21666210216122022
Khaja S M Abdul, Neha Faiz, Aleksandar Jovanović, Wen Tan

Aims: In the present study, we have investigated the cardioprotective properties of Isosteviol (STV) under conditions of hypoxia-reoxygenation and elucidated the underlying mechanism.

Background: In our previous studies, we have determined that STV exhibits neuro- and cardio-protective properties. However, the mechanism underlying STV-induced cardioprotection has not yet been fully understood.

Methods: All experiments were performed on rat heart embryonic H9c2 cell line. To induce hypoxia- reoxygenation, cells were exposed to 1% oxygen (in no glucose and no sodium pyruvate DMEM) following by reoxygenation (using fully supplemented MEM). Cells viability was tested by MTT assay, and protein levels were compared by Western blotting.

Results: Treatment of heart embryonic H9c2 cells with STV (10 μM) significantly increased the survival of cells exposed to hypoxia-reoxygenation. STV (10 μM) activated ERK1/2 and DRP1 in hypoxia-reoxygenation, but did not have any effects on ERK1/2 or DRP1 in normoxia. STV (10 μM) did not regulate CAMKII, AKT or AMPK signaling pathways.

Conclusion: Taken all together, our findings demonstrate that 1) STV protects H9c2 cells against hypoxia-reoxygenation and that 2) this effect is mediated via ERK1/2. The property of STV that selectively activates ERK1/2 in cells exposed to stress, but not in cells under non-stress conditions, makes this compound a promising candidate-drug for therapy against myocardial ischemia-reperfusion in clinical practice.

目的:研究异甜菊醇(issteviol, STV)在缺氧-复氧条件下的心脏保护作用,并阐明其机制。背景:在我们之前的研究中,我们已经确定STV具有神经和心脏保护特性。然而,stv诱导的心脏保护机制尚不完全清楚。方法:采用大鼠心脏胚胎H9c2细胞系进行实验。为了诱导缺氧再氧化,将细胞暴露于1%的氧气(无葡萄糖和无丙酮酸钠DMEM)中,然后再氧化(使用充分补充的MEM)。MTT法检测细胞活力,Western blotting法比较蛋白水平。结果:STV (10 μM)处理心脏胚胎H9c2细胞可显著提高缺氧复氧细胞的存活率。STV (10 μM)在低氧复氧条件下激活ERK1/2和DRP1,而在常氧条件下对ERK1/2和DRP1无影响。STV (10 μM)不调节CAMKII、AKT和AMPK信号通路。结论:综上所述,我们的研究结果表明1)STV保护H9c2细胞免受缺氧再氧化,2)这种作用是通过ERK1/2介导的。STV选择性激活应激条件下细胞的ERK1/2,而非应激条件下细胞的ERK1/2,这使得该化合物在临床实践中成为治疗心肌缺血再灌注的有希望的候选药物。
{"title":"Isosteviol Protects H9c2 Cells Against Hypoxia-reoxygenation by Activating ERK1/2.","authors":"Khaja S M Abdul,&nbsp;Neha Faiz,&nbsp;Aleksandar Jovanović,&nbsp;Wen Tan","doi":"10.2174/1871529X21666210216122022","DOIUrl":"https://doi.org/10.2174/1871529X21666210216122022","url":null,"abstract":"<p><strong>Aims: </strong>In the present study, we have investigated the cardioprotective properties of Isosteviol (STV) under conditions of hypoxia-reoxygenation and elucidated the underlying mechanism.</p><p><strong>Background: </strong>In our previous studies, we have determined that STV exhibits neuro- and cardio-protective properties. However, the mechanism underlying STV-induced cardioprotection has not yet been fully understood.</p><p><strong>Methods: </strong>All experiments were performed on rat heart embryonic H9c2 cell line. To induce hypoxia- reoxygenation, cells were exposed to 1% oxygen (in no glucose and no sodium pyruvate DMEM) following by reoxygenation (using fully supplemented MEM). Cells viability was tested by MTT assay, and protein levels were compared by Western blotting.</p><p><strong>Results: </strong>Treatment of heart embryonic H9c2 cells with STV (10 μM) significantly increased the survival of cells exposed to hypoxia-reoxygenation. STV (10 μM) activated ERK1/2 and DRP1 in hypoxia-reoxygenation, but did not have any effects on ERK1/2 or DRP1 in normoxia. STV (10 μM) did not regulate CAMKII, AKT or AMPK signaling pathways.</p><p><strong>Conclusion: </strong>Taken all together, our findings demonstrate that 1) STV protects H9c2 cells against hypoxia-reoxygenation and that 2) this effect is mediated via ERK1/2. The property of STV that selectively activates ERK1/2 in cells exposed to stress, but not in cells under non-stress conditions, makes this compound a promising candidate-drug for therapy against myocardial ischemia-reperfusion in clinical practice.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 1","pages":"73-77"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25374413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Congenital Heart Disease among Children in Khorramabad (West of Iran). 霍拉马巴德(伊朗西部)儿童先天性心脏病患病率
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871529X20999201231205746
Alireza Nezami, Ghobad Heidari, Fariba Tarhani, Masoumeh Kariminia

Aims: Congenital heart disease is among the most common congenital anomalies in pediatrics. The aim of this study was to evaluate the prevalence of congenital heart disease in children in Khorramabad, Iran.

Methods: This is a descriptive-cross sectional study where all the children diagnosed with congenital heart disease by echocardiography were enrolled to the Shahid Madani Hospital. Patient information was collected by means of a questionnaire. Of 1600 children who underwent cardiac counseling, 9.75% presented congenital heart disease. These were most prevalent among the children of 0-28 days of the age (14.7%) and least in children aged 1 month-1 year. According to this study, atrial (20.3%) and ventricular septal defect (10.5%) were the most common heart defects, respectively. Among signs and symptoms of cardiac disease, 49.1% of children had cyanosis, 89.7% with increased CT (cardiothoracic)-ratio, and 82.7% of had heart murmur. Congenital heart disease was more prevalent in male infants (58%) and 6.6% patients had heart failure and 1.4% had other congenital conditions, such as Down syndrome.

Results: According to our findings, atrial and ventricular septal defects are the most common congenital heart anomalies, respectively, in pediatric patients in Khorramabad.

目的:先天性心脏病是儿科最常见的先天性异常之一。本研究的目的是评估伊朗霍拉马巴德儿童先天性心脏病的患病率。方法:这是一项描述性横断面研究,所有通过超声心动图诊断为先天性心脏病的儿童都被纳入Shahid Madani医院。通过问卷调查收集患者信息。在1600名接受心脏咨询的儿童中,9.75%患有先天性心脏病。这些在0-28天的儿童中最为普遍(14.7%),在1个月-1岁的儿童中最少。根据本研究,心房(20.3%)和室间隔缺损(10.5%)分别是最常见的心脏缺陷。在心脏病的体征和症状中,49.1%的儿童有紫绀,89.7%的儿童有CT(心胸)比增高,82.7%的儿童有心脏杂音。先天性心脏病在男婴中更为普遍(58%),6.6%的患者患有心力衰竭,1.4%的患者患有其他先天性疾病,如唐氏综合症。结果:根据我们的研究结果,心房和室间隔缺损分别是最常见的先天性心脏异常,在霍拉马巴德的儿科患者。
{"title":"Prevalence of Congenital Heart Disease among Children in Khorramabad (West of Iran).","authors":"Alireza Nezami,&nbsp;Ghobad Heidari,&nbsp;Fariba Tarhani,&nbsp;Masoumeh Kariminia","doi":"10.2174/1871529X20999201231205746","DOIUrl":"https://doi.org/10.2174/1871529X20999201231205746","url":null,"abstract":"<p><strong>Aims: </strong>Congenital heart disease is among the most common congenital anomalies in pediatrics. The aim of this study was to evaluate the prevalence of congenital heart disease in children in Khorramabad, Iran.</p><p><strong>Methods: </strong>This is a descriptive-cross sectional study where all the children diagnosed with congenital heart disease by echocardiography were enrolled to the Shahid Madani Hospital. Patient information was collected by means of a questionnaire. Of 1600 children who underwent cardiac counseling, 9.75% presented congenital heart disease. These were most prevalent among the children of 0-28 days of the age (14.7%) and least in children aged 1 month-1 year. According to this study, atrial (20.3%) and ventricular septal defect (10.5%) were the most common heart defects, respectively. Among signs and symptoms of cardiac disease, 49.1% of children had cyanosis, 89.7% with increased CT (cardiothoracic)-ratio, and 82.7% of had heart murmur. Congenital heart disease was more prevalent in male infants (58%) and 6.6% patients had heart failure and 1.4% had other congenital conditions, such as Down syndrome.</p><p><strong>Results: </strong>According to our findings, atrial and ventricular septal defects are the most common congenital heart anomalies, respectively, in pediatric patients in Khorramabad.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 1","pages":"61-65"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38774258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Post-Discharge Prophylactic Anticoagulation in COVID-19 Patients: A Clinical Dilemma. COVID-19患者出院后预防性抗凝:一个临床困境。
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871529X21666210914113752
Prakrati Yadav, Deepak Kumar, Durga S Meena, Naresh K Midha, Gopal K Bohra, Mahendra K Garg, Abhishek H L Purohit

Background: COVID-19 pandemic has taken a great toll on the health care system worldwide. Along with the pandemic, there is also a concern regarding post COVID-19 complications in recovered patients. Thromboembolism (TE) has been reported as a fatal complication in recovered patients with COVID-19. There is still a great dilemma in post-discharge TE prophylaxis and its long-term benefits.

Case description: We reported three cases of post COVID-19 with complications related to both diseases as well as post discharge anticoagulant therapy. The first case is about a 60-yr-old male who developed Covid-19 pneumonia (moderate disease) and was discharged on rivaroxaban after initial improvement. 3 weeks later, the patient was readmitted with lower gastro-intestinal bleeding. The other two cases developed pulmonary thromboembolism within a span of 2-3 months (after recovered from COVID-19 pneumonia). Both these patients were not prescribed anticoagulants for TE prophylaxis.

Conclusion: There is an imperative need for effective guidelines for post discharge TE prophylaxis in COVID-19.

背景:2019冠状病毒病大流行给全球卫生保健系统造成了巨大损失。除了大流行之外,人们还担心康复患者的COVID-19后并发症。据报道,血栓栓塞(TE)是COVID-19康复患者的致命并发症。在出院后TE预防及其长期效益方面仍然存在很大的困境。病例描述:我们报告了3例COVID-19后合并两种疾病相关并发症以及出院后抗凝治疗的病例。第一个病例是一名60岁的男性,他患上了Covid-19肺炎(中度疾病),初步好转后使用利伐沙班出院。3周后,患者因下消化道出血再次入院。另外2例在2-3个月内(COVID-19肺炎康复后)发生肺血栓栓塞。这两名患者均未使用抗凝剂预防TE。结论:迫切需要制定有效的COVID-19患者出院后TE预防指南。
{"title":"Post-Discharge Prophylactic Anticoagulation in COVID-19 Patients: A Clinical Dilemma.","authors":"Prakrati Yadav,&nbsp;Deepak Kumar,&nbsp;Durga S Meena,&nbsp;Naresh K Midha,&nbsp;Gopal K Bohra,&nbsp;Mahendra K Garg,&nbsp;Abhishek H L Purohit","doi":"10.2174/1871529X21666210914113752","DOIUrl":"https://doi.org/10.2174/1871529X21666210914113752","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 pandemic has taken a great toll on the health care system worldwide. Along with the pandemic, there is also a concern regarding post COVID-19 complications in recovered patients. Thromboembolism (TE) has been reported as a fatal complication in recovered patients with COVID-19. There is still a great dilemma in post-discharge TE prophylaxis and its long-term benefits.</p><p><strong>Case description: </strong>We reported three cases of post COVID-19 with complications related to both diseases as well as post discharge anticoagulant therapy. The first case is about a 60-yr-old male who developed Covid-19 pneumonia (moderate disease) and was discharged on rivaroxaban after initial improvement. 3 weeks later, the patient was readmitted with lower gastro-intestinal bleeding. The other two cases developed pulmonary thromboembolism within a span of 2-3 months (after recovered from COVID-19 pneumonia). Both these patients were not prescribed anticoagulants for TE prophylaxis.</p><p><strong>Conclusion: </strong>There is an imperative need for effective guidelines for post discharge TE prophylaxis in COVID-19.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 3","pages":"206-209"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39415567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Composite Study of Coagulation Milieu in Covid-19: Experience from a Tertiary Care Centre from India. Covid-19凝血环境的综合研究:来自印度三级医疗中心的经验
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871529X21666211201110007
Gopal K Bohra, Abhishek Purohit, Deepak Kumar, Mahendra K Garg, Naresh K Midha, Ravi Manglia, Kartik Jain, Siyaram Didel, Vijayalakshami Nag, Praveen Sharma, Ankur Sharma, Pradeep Bhatia, Sanjeev Misra

Background: The understanding of pathogenesis is necessary for the development of effective treatment for COVID-19. Various studies have postulated that there is a complex interplay of mediators of coagulation and inflammation responsible for the pathogenesis of COVID-19. We did this study on coagulation parameters and inflammatory markers and their effect on outcome in patients with COVID-19.

Methods: This was a single centre observational cross-sectional study. Procoagulants [Prothrombin time (PT), activated partial thromboplastin time (APTT), D-dimer, lupus anticoagulant (LA), fibrinogen, factor-VIII (F-VIII)]; anticoagulants [protein-C (PC), protein-S (PS), antithrombin] and inflammatory markers [interleukin-6 (IL-6) and highly sensitive - C-reactive protein (hs-CRP)] were measured at the time of hospitalization and correlated with the severity of the disease.

Results: A total of 230 patients were enrolled, of which 61.3%, 20.0%, and 18.7% had asymptomatic/ mild, moderate, or severe disease, respectively. COVID-19 disease severity was associated with rising trends with coagulation parameters (PT, APTT, D-Dimer; p value 0.01, <0.0001, <0.0001, respectively). Falling trends of anticoagulant (PC, Antithrombin; p value <0.0001, 0.003 respectively) and rising trends of procoagulant (fibrinogen, F-VIII; p value 0.004, <0.0001 respectively) were observed with increasing COVID-19 disease severity. Multivariate logistic regression analysis found that advanced age, high D-Dimer, and high hs-CRP (p value 0.035, 0.018, <0.0001 respectively) were independent predictors of mortality in COVID-19. Procoagulant parameters (D-dimer, APTT, Factor VIII) were positively correlated with anticoagulant parameters (PC and PS) and inflammatory parameters (hs-CRP).

Conclusion: This study revealed increased levels of coagulation and inflammatory parameters, which correlated with the severity of COVID-19. Age, D-dimer, IL-6, hs-CRP, APTT, fibrinogen, and Factor VIII were significantly higher in patients with moderate and severe disease as compared to asymptomatic/mild disease. Advanced age, high D-dimer, and high hs-CRP were significantly associated with poor outcomes.

背景:了解新冠肺炎的发病机制是制定有效治疗方案的必要条件。各种研究假设,COVID-19的发病机制与凝血和炎症介质之间存在复杂的相互作用。我们对COVID-19患者的凝血参数和炎症标志物及其对预后的影响进行了研究。方法:这是一项单中心观察性横断面研究。促凝剂[凝血酶原时间(PT)、活化的部分凝血活素时间(APTT)、d -二聚体、狼疮抗凝剂(LA)、纤维蛋白原、因子- viii (F-VIII)];在住院时测定抗凝血剂[蛋白- c (PC)、蛋白- s (PS)、抗凝血酶]和炎症标志物[白细胞介素-6 (IL-6)和高敏感c反应蛋白(hs-CRP)],并与疾病严重程度相关。结果:共纳入230例患者,其中61.3%、20.0%和18.7%分别为无症状/轻度、中度或重度疾病。COVID-19疾病严重程度与凝血参数(PT、APTT、d -二聚体;结论:本研究显示凝血和炎症参数水平升高与COVID-19严重程度相关。年龄、d -二聚体、IL-6、hs-CRP、APTT、纤维蛋白原和因子VIII在中度和重度疾病患者中明显高于无症状/轻度疾病患者。高龄、高d -二聚体和高hs-CRP与不良预后显著相关。
{"title":"A Composite Study of Coagulation Milieu in Covid-19: Experience from a Tertiary Care Centre from India.","authors":"Gopal K Bohra,&nbsp;Abhishek Purohit,&nbsp;Deepak Kumar,&nbsp;Mahendra K Garg,&nbsp;Naresh K Midha,&nbsp;Ravi Manglia,&nbsp;Kartik Jain,&nbsp;Siyaram Didel,&nbsp;Vijayalakshami Nag,&nbsp;Praveen Sharma,&nbsp;Ankur Sharma,&nbsp;Pradeep Bhatia,&nbsp;Sanjeev Misra","doi":"10.2174/1871529X21666211201110007","DOIUrl":"https://doi.org/10.2174/1871529X21666211201110007","url":null,"abstract":"<p><strong>Background: </strong>The understanding of pathogenesis is necessary for the development of effective treatment for COVID-19. Various studies have postulated that there is a complex interplay of mediators of coagulation and inflammation responsible for the pathogenesis of COVID-19. We did this study on coagulation parameters and inflammatory markers and their effect on outcome in patients with COVID-19.</p><p><strong>Methods: </strong>This was a single centre observational cross-sectional study. Procoagulants [Prothrombin time (PT), activated partial thromboplastin time (APTT), D-dimer, lupus anticoagulant (LA), fibrinogen, factor-VIII (F-VIII)]; anticoagulants [protein-C (PC), protein-S (PS), antithrombin] and inflammatory markers [interleukin-6 (IL-6) and highly sensitive - C-reactive protein (hs-CRP)] were measured at the time of hospitalization and correlated with the severity of the disease.</p><p><strong>Results: </strong>A total of 230 patients were enrolled, of which 61.3%, 20.0%, and 18.7% had asymptomatic/ mild, moderate, or severe disease, respectively. COVID-19 disease severity was associated with rising trends with coagulation parameters (PT, APTT, D-Dimer; p value 0.01, <0.0001, <0.0001, respectively). Falling trends of anticoagulant (PC, Antithrombin; p value <0.0001, 0.003 respectively) and rising trends of procoagulant (fibrinogen, F-VIII; p value 0.004, <0.0001 respectively) were observed with increasing COVID-19 disease severity. Multivariate logistic regression analysis found that advanced age, high D-Dimer, and high hs-CRP (p value 0.035, 0.018, <0.0001 respectively) were independent predictors of mortality in COVID-19. Procoagulant parameters (D-dimer, APTT, Factor VIII) were positively correlated with anticoagulant parameters (PC and PS) and inflammatory parameters (hs-CRP).</p><p><strong>Conclusion: </strong>This study revealed increased levels of coagulation and inflammatory parameters, which correlated with the severity of COVID-19. Age, D-dimer, IL-6, hs-CRP, APTT, fibrinogen, and Factor VIII were significantly higher in patients with moderate and severe disease as compared to asymptomatic/mild disease. Advanced age, high D-dimer, and high hs-CRP were significantly associated with poor outcomes.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 3","pages":"185-195"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39772350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aqueous Extract of Brassica rapa Exerts Antihyperglycemic Activity in Streptozotocin-induced Diabetic Rats. 油菜水提物对链脲佐菌素诱导的糖尿病大鼠的降糖作用。
Q2 Medicine Pub Date : 2021-01-01 DOI: 10.2174/1871529X21666211209114436
Ismail Bouadid, Ayoub Amssayef, Nadia Lahrach, Ahmed El-Haidani, Mohamed Eddouks

Aims: The aim of the study was to assess the antihyperglycemic effect of Brassica rapa.

Background: Brassica rapa (turnip) is used as an antidiabetic plant.

Objective: This work aimed to evaluate the effect of the aqueous extract of Brassica rapa seeds (AEBRS) on glycemia in vivo.

Methods: The effect of AEBRS (60 mg/kg) on glycemia and lipid profiles was evaluated. Besides, preliminary phytochemical analysis and the in vitro antioxidant effect were evaluated.

Results: AEBRS caused a significant reduction in blood glucose levels in diabetic rats (p<0.0001). In contrast, no significant effect was observed on lipid profiles, whereas antioxidant potential of this extract has been shown. Phytochemical analysis showed the presence of many important phytochemical families.

Conclusion: The present study shows that AEBRS has a potent antihyperglycemic ability in diabetic rats.

目的:研究油菜的降血糖作用。背景:芜菁(Brassica rapa)被用作抗糖尿病植物。目的:研究油菜籽水提物(AEBRS)对体内血糖的影响。方法:观察AEBRS (60 mg/kg)对血糖和血脂的影响。此外,还进行了初步的植物化学分析和体外抗氧化效果评价。结果:AEBRS能显著降低糖尿病大鼠的血糖水平(结论:AEBRS对糖尿病大鼠具有明显的降糖作用。
{"title":"Aqueous Extract of Brassica rapa Exerts Antihyperglycemic Activity in Streptozotocin-induced Diabetic Rats.","authors":"Ismail Bouadid,&nbsp;Ayoub Amssayef,&nbsp;Nadia Lahrach,&nbsp;Ahmed El-Haidani,&nbsp;Mohamed Eddouks","doi":"10.2174/1871529X21666211209114436","DOIUrl":"https://doi.org/10.2174/1871529X21666211209114436","url":null,"abstract":"<p><strong>Aims: </strong>The aim of the study was to assess the antihyperglycemic effect of Brassica rapa.</p><p><strong>Background: </strong>Brassica rapa (turnip) is used as an antidiabetic plant.</p><p><strong>Objective: </strong>This work aimed to evaluate the effect of the aqueous extract of Brassica rapa seeds (AEBRS) on glycemia in vivo.</p><p><strong>Methods: </strong>The effect of AEBRS (60 mg/kg) on glycemia and lipid profiles was evaluated. Besides, preliminary phytochemical analysis and the in vitro antioxidant effect were evaluated.</p><p><strong>Results: </strong>AEBRS caused a significant reduction in blood glucose levels in diabetic rats (p<0.0001). In contrast, no significant effect was observed on lipid profiles, whereas antioxidant potential of this extract has been shown. Phytochemical analysis showed the presence of many important phytochemical families.</p><p><strong>Conclusion: </strong>The present study shows that AEBRS has a potent antihyperglycemic ability in diabetic rats.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 4","pages":"253-259"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39798900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects. 辛伐他汀对冠心病联合二级预防中脂肪酸代谢的影响:剂量和性别差异
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20666200109144353
Mikhail Y Kotlovskiy, Elena V Udut, Gaisa T Kairov, Vladimir P Fisenko, Vladimir V Udut

Background: Statins are currently used for secondary prevention of Coronary Heart Disease (CHD), as the lipid-lowering therapy with them is proven safe and effective.

Objective: The purpose of this research is to investigate the dose-dependent effect of statins used for secondary prevention of coronary heart disease, as well as mechanisms of quantitative and qualitative changes in lipoproteins, fatty acids and cholesterol in the blood and tissues of people of both sexes.

Methods: In a clinical trial (n=125, of which 89 patients belong to group 1 and 36 to group 2) and an experiment on laboratory animals (n = 100), simvastatin reduced the total level of fatty acids in blood plasma, when given in the amount that was within the therapeutic dose range.

Results: This effect was achieved through a drug-induced improvement in the capacity of hepatic cells to absorb Low-density (LDL) and Very-low-density (VLDL) lipoproteins.

Conclusion: Considering the formation of saturated fatty acids, statin performed better in males. With Omega-3 polyunsaturated fatty acids involved, changes in lipoproteins, cholesterol and fatty acids (liver and myocardium) were similar to those caused by small doses of a statin drug. Effects of the combination of bisoprolol and acetylsalicylic acid were completely different from those caused by the use of statin.

背景:由于他汀类药物的降脂治疗被证明是安全有效的,目前他汀类药物被用于冠心病的二级预防。目的:本研究旨在探讨他汀类药物用于冠心病二级预防的剂量依赖效应,以及男女人群血液和组织中脂蛋白、脂肪酸、胆固醇的定量和质变机制。方法:临床试验125例(其中1组89例,2组36例)和实验动物实验100例(n= 100),在治疗剂量范围内给予辛伐他汀可降低血浆脂肪酸总水平。结果:这种效果是通过药物诱导的肝细胞吸收低密度(LDL)和极低密度(VLDL)脂蛋白的能力的改善实现的。结论:考虑到饱和脂肪酸的形成,他汀类药物在男性中表现更好。与Omega-3多不饱和脂肪酸有关,脂蛋白、胆固醇和脂肪酸(肝脏和心肌)的变化与小剂量他汀类药物引起的变化相似。比索洛尔与乙酰水杨酸联用的效果与他汀类药物完全不同。
{"title":"Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects.","authors":"Mikhail Y Kotlovskiy,&nbsp;Elena V Udut,&nbsp;Gaisa T Kairov,&nbsp;Vladimir P Fisenko,&nbsp;Vladimir V Udut","doi":"10.2174/1871529X20666200109144353","DOIUrl":"https://doi.org/10.2174/1871529X20666200109144353","url":null,"abstract":"<p><strong>Background: </strong>Statins are currently used for secondary prevention of Coronary Heart Disease (CHD), as the lipid-lowering therapy with them is proven safe and effective.</p><p><strong>Objective: </strong>The purpose of this research is to investigate the dose-dependent effect of statins used for secondary prevention of coronary heart disease, as well as mechanisms of quantitative and qualitative changes in lipoproteins, fatty acids and cholesterol in the blood and tissues of people of both sexes.</p><p><strong>Methods: </strong>In a clinical trial (n=125, of which 89 patients belong to group 1 and 36 to group 2) and an experiment on laboratory animals (n = 100), simvastatin reduced the total level of fatty acids in blood plasma, when given in the amount that was within the therapeutic dose range.</p><p><strong>Results: </strong>This effect was achieved through a drug-induced improvement in the capacity of hepatic cells to absorb Low-density (LDL) and Very-low-density (VLDL) lipoproteins.</p><p><strong>Conclusion: </strong>Considering the formation of saturated fatty acids, statin performed better in males. With Omega-3 polyunsaturated fatty acids involved, changes in lipoproteins, cholesterol and fatty acids (liver and myocardium) were similar to those caused by small doses of a statin drug. Effects of the combination of bisoprolol and acetylsalicylic acid were completely different from those caused by the use of statin.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 2","pages":"93-107"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37525447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Is the Detection of Factor IX Inhibitors in Hemophilia B Orphan than Factor VIII Inhibitors in Hemophilia A? A Concise, Systematic Review. 血友病B孤儿中因子IX抑制剂的检测是否优于因子VIII抑制剂在血友病A中的检测?一篇简明、系统的综述。
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20666200701104143
Hassan Mansouritorghabeh, Seyedeh T Mohades

Objective: Development of inhibitors in hemophilia A and B comprise significant challenge for patients, hematologists, and health provider systems. It has recommended by the World Federation of Hemophilia (WFH) to check inhibitors every 3-4 months. The incidence of inhibitor in hemophilia B is lower than hemophilia A. Here, it tried to unravel whether the detection of inhibitors in hemophilia B neglected compared to hemophilia A or not?

Methods: A comprehensive review carried out using six international and local medical search engines on published contributions about inhibitors in hemophilia A and B in Iran.

Results: From 699 titles, 12 relevant papers were selected. The mean of factor VIII inhibitors in hemophilia A was 14.8%. The mean of factor IX inhibitors in hemophilia B was 6%. The minimum and maximum reported percentages of factor VIII inhibitors were 4% and 19.6%, while the minimum and maximum of reported percentages of factor IX inhibitors were 0% and 11.8%, respectively. The inhibitors in hemophilia A had reported in 6 papers. One paper had covered the inhibitors in hemophilia B. There were five papers on inhibitors in both hemophilia A and B. The comparison between the reported patients showed that 3020 patients with hemophilia A and 314 patients with hemophilia B had studied.

Conclusion: Consistent with the lower frequency of hemophilia B and the lower development of inhibitors in hemophilia B compared to hemophilia A, it was concluded that hemophilia B had not neglected in Iran. It seems to be rational that each country, check rates of detection of inhibitors in hemophilia B to identify whether it has neglected or not.

目的:血友病A和B抑制剂的开发对患者、血液病学家和卫生保健提供者系统构成了重大挑战。世界血友病联合会(WFH)建议每3-4个月检查一次抑制剂。B型血友病中抑制剂的发生率低于A型血友病。本文试图揭示B型血友病中抑制剂的检测是否与A型血友病相比被忽视?方法:使用6个国际和本地医学搜索引擎对伊朗血友病A和B抑制剂发表的贡献进行综合评价。结果:从699篇文献中筛选出12篇相关论文。血友病A中因子VIII抑制剂的平均值为14.8%。因子IX抑制剂在B型血友病中的平均使用率为6%。因子VIII抑制剂的最小和最大报告百分比分别为4%和19.6%,而因子IX抑制剂的最小和最大报告百分比分别为0%和11.8%。A型血友病的抑制剂已有6篇文献报道。1篇论文报道了B型血友病的抑制剂,5篇论文报道了A型血友病和B型血友病的抑制剂。对比报道的患者,3020例A型血友病患者和314例B型血友病患者被研究。结论:与血友病A相比,血友病B的发病率较低,血友病B抑制剂的发展较低,这表明血友病B在伊朗并没有被忽视。每个国家都应检查B型血友病抑制剂的检出率,以确定是否被忽视,这似乎是合理的。
{"title":"Is the Detection of Factor IX Inhibitors in Hemophilia B Orphan than Factor VIII Inhibitors in Hemophilia A? A Concise, Systematic Review.","authors":"Hassan Mansouritorghabeh,&nbsp;Seyedeh T Mohades","doi":"10.2174/1871529X20666200701104143","DOIUrl":"https://doi.org/10.2174/1871529X20666200701104143","url":null,"abstract":"<p><strong>Objective: </strong>Development of inhibitors in hemophilia A and B comprise significant challenge for patients, hematologists, and health provider systems. It has recommended by the World Federation of Hemophilia (WFH) to check inhibitors every 3-4 months. The incidence of inhibitor in hemophilia B is lower than hemophilia A. Here, it tried to unravel whether the detection of inhibitors in hemophilia B neglected compared to hemophilia A or not?</p><p><strong>Methods: </strong>A comprehensive review carried out using six international and local medical search engines on published contributions about inhibitors in hemophilia A and B in Iran.</p><p><strong>Results: </strong>From 699 titles, 12 relevant papers were selected. The mean of factor VIII inhibitors in hemophilia A was 14.8%. The mean of factor IX inhibitors in hemophilia B was 6%. The minimum and maximum reported percentages of factor VIII inhibitors were 4% and 19.6%, while the minimum and maximum of reported percentages of factor IX inhibitors were 0% and 11.8%, respectively. The inhibitors in hemophilia A had reported in 6 papers. One paper had covered the inhibitors in hemophilia B. There were five papers on inhibitors in both hemophilia A and B. The comparison between the reported patients showed that 3020 patients with hemophilia A and 314 patients with hemophilia B had studied.</p><p><strong>Conclusion: </strong>Consistent with the lower frequency of hemophilia B and the lower development of inhibitors in hemophilia B compared to hemophilia A, it was concluded that hemophilia B had not neglected in Iran. It seems to be rational that each country, check rates of detection of inhibitors in hemophilia B to identify whether it has neglected or not.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 3","pages":"185-190"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38106844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction. 入院时间血细胞计数(CBC)参数对st段抬高型心肌梗死患者经皮冠状动脉介入治疗后TIMI框架计数的预测价值
Q2 Medicine Pub Date : 2020-01-01 DOI: 10.2174/1871529X20666200206123118
Hossein Vakili, Isa Khaheshi, Amirsina Sharifi, Negin Nickdoost, Mohammad H Namazi, Morteza Safi, Habibollah Saadat, Saeed A Parsa, Mohammad A Akbarzadeh, Mohammadreza Naderian, Negin Yousefi, Mahin Shirazi, Mohammadreza Tabary

Objectives: In this study, we aimed to assess the value of admission time CBC parameters in predicting post-primary PCI corrected TIMI frame count.

Background: Recent years have witnessed a large series of studies evaluating different laboratory variables to predict no-reflow phenomenon following primary PCI (PPCI) in patients with STEMI. However, a general agreement about the most reliable predictor of the no-reflow phenomenon is challenging and also intriguing.

Methods: The current study concluded 208 consecutive patients who underwent primary PCI for ST-Elevation Myocardial Infarction (STEMI) from January 2014 to February 2016. Blood samples were obtained after taking ECG. Complete blood samples were collected and analyzed within 5 minutes from sampling. Post-PCI corrected Thrombolysis in Myocardial Infarction (TIMI) frame count was determined by one interventional cardiologist blinded to patients' clinical data. The correlation between admission time blood parameters and post-primary PCI corrected TIMI frame count in patients with STEMI were assessed.

Results: Corrected TIMI frame count was positively correlated with WBC count (R: 0.18, P-value: <0.01), neutrophil count (R: 0.34, P-value: <0.01), and platelet count (R: 0.23, P-value: <0.01) and negatively correlated with lymphocyte count (R: -0.2, P-value: <0.01). Multiple linear regression results demonstrated that corrected TIMI frame count was positively correlated with neutrophil count (P < 0·001) and platelet count (P < 0·001) and negatively correlated with lymphocyte count (p=0.004).

Conclusion: High counts of WBC, neutrophil, and platelet and low count of lymphocyte may be predictors of no-reflow in STEMI patients undergoing PPCI. The clinical significance of such predictive parameters becomes clear as we consider the treatment approach in STEMI patients. Appropriate risk stratification leads to better treatment planning and allocation of resources.

目的:在本研究中,我们旨在评估入院时间CBC参数在预测原发性PCI校正后TIMI帧计数中的价值。背景:近年来进行了大量的研究,评估不同的实验室变量来预测STEMI患者初次PCI (PPCI)后的无再流现象。然而,关于无回流现象最可靠的预测器的普遍共识是具有挑战性的,也是有趣的。方法:本研究总结了2014年1月至2016年2月期间连续208例因st段抬高型心肌梗死(STEMI)接受首次PCI治疗的患者。取心电图后取血样。采集完整的血液样本并在5分钟内进行分析。pci校正后的心肌梗死溶栓(TIMI)帧数由一名对患者临床数据不知情的介入性心脏病专家确定。评估STEMI患者入院时间血液参数与初次PCI校正后TIMI框架计数的相关性。结果:校正后的TIMI框架计数与WBC计数呈正相关(R: 0.18, p值:结论:WBC、中性粒细胞和血小板计数高,淋巴细胞计数低可能是STEMI患者行PPCI后无再流的预测因素。当我们考虑STEMI患者的治疗方法时,这些预测参数的临床意义变得清晰。适当的风险分层导致更好的治疗计划和资源分配。
{"title":"Assessment of Admission Time Cell Blood Count (CBC) Parameters in Predicting Post-primary Percutaneous Coronary Intervention TIMI Frame Count in Patients with ST-segment Elevation Myocardial Infarction.","authors":"Hossein Vakili,&nbsp;Isa Khaheshi,&nbsp;Amirsina Sharifi,&nbsp;Negin Nickdoost,&nbsp;Mohammad H Namazi,&nbsp;Morteza Safi,&nbsp;Habibollah Saadat,&nbsp;Saeed A Parsa,&nbsp;Mohammad A Akbarzadeh,&nbsp;Mohammadreza Naderian,&nbsp;Negin Yousefi,&nbsp;Mahin Shirazi,&nbsp;Mohammadreza Tabary","doi":"10.2174/1871529X20666200206123118","DOIUrl":"https://doi.org/10.2174/1871529X20666200206123118","url":null,"abstract":"<p><strong>Objectives: </strong>In this study, we aimed to assess the value of admission time CBC parameters in predicting post-primary PCI corrected TIMI frame count.</p><p><strong>Background: </strong>Recent years have witnessed a large series of studies evaluating different laboratory variables to predict no-reflow phenomenon following primary PCI (PPCI) in patients with STEMI. However, a general agreement about the most reliable predictor of the no-reflow phenomenon is challenging and also intriguing.</p><p><strong>Methods: </strong>The current study concluded 208 consecutive patients who underwent primary PCI for ST-Elevation Myocardial Infarction (STEMI) from January 2014 to February 2016. Blood samples were obtained after taking ECG. Complete blood samples were collected and analyzed within 5 minutes from sampling. Post-PCI corrected Thrombolysis in Myocardial Infarction (TIMI) frame count was determined by one interventional cardiologist blinded to patients' clinical data. The correlation between admission time blood parameters and post-primary PCI corrected TIMI frame count in patients with STEMI were assessed.</p><p><strong>Results: </strong>Corrected TIMI frame count was positively correlated with WBC count (R: 0.18, P-value: <0.01), neutrophil count (R: 0.34, P-value: <0.01), and platelet count (R: 0.23, P-value: <0.01) and negatively correlated with lymphocyte count (R: -0.2, P-value: <0.01). Multiple linear regression results demonstrated that corrected TIMI frame count was positively correlated with neutrophil count (P < 0·001) and platelet count (P < 0·001) and negatively correlated with lymphocyte count (p=0.004).</p><p><strong>Conclusion: </strong>High counts of WBC, neutrophil, and platelet and low count of lymphocyte may be predictors of no-reflow in STEMI patients undergoing PPCI. The clinical significance of such predictive parameters becomes clear as we consider the treatment approach in STEMI patients. Appropriate risk stratification leads to better treatment planning and allocation of resources.</p>","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 3","pages":"191-197"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37615967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Cardiovascular and Hematological Disorders - Drug Targets
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1